JDB153

N/A

Report date: 2026/01/21 20:00:47
NME

Base Information

Drug NameJDB153
Drug Alias NameJDB153
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMAP kinase-interacting serine/threonine-protein kinase MNK1 inhibitorsMAP kinase-interacting serine/threonine-protein kinase 2 inhibitorsVascular endothelial growth factor receptor antagonists
TargetsMAP kinase-interacting serine/threonine-protein kinase MNK1MAP kinase-interacting serine/threonine-protein kinase 2Vascular endothelial growth factor receptor
Therapy Area/IndicationsSolid tumoursCarcinoma, Pancreatic DuctalAdenocarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Jiabao Yaoyin Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesWest China Hospital Of Sichuan University
Inactive CompaniesShanghai Jiabao Yaoyin Pharmaceutical Technology Co Ltd
Active IndicationsCarcinoma, Pancreatic DuctalAdenocarcinoma
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A